Healthcare Equipment and Supplies
Company Overview of Sera Prognostics, Inc.
Sera Prognostics, Inc., a biotechnology company, develops diagnostic and blood tests that help physicians to predict and manage preterm birth, preeclampsia, and other pregnancy complications. Sera Prognostics, Inc. has a strategic partnership with Agilent Technologies Inc. The company was founded in 2008 and is based in Salt Lake City, Utah.
2749 East Parleys Way
Salt Lake City, UT 84109
Founded in 2008
Key Executives for Sera Prognostics, Inc.
Co-Founder and Co-Chairman of The Scientific Advisory Board
Co-Founder and Co-Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2013.
Sera Prognostics, Inc. Key Developments
Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health
Feb 12 13
Agilent Technologies Inc. and Sera Prognostics Inc. announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications. As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production. The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.
Sera Prognostics, Inc. Appoints Ilia Ichetovkin as Vice President of Laboratory Operations
Oct 3 12
Sera Prognostics, Inc. announced the appointment of Ilia Ichetovkin, as Vice President of Laboratory Operations. Dr. Ichetovkin will lead the development and deployment of Sera's CLIA laboratory services, culminating in the commercial launch of ProNid(TM), Sera's innovative diagnostic test to predict preterm birth risk. Before joining Sera, Dr. Ichetovkin served for ten years at companies developing and providing novel diagnostic laboratory services in a number of areas of molecular oncology and maternal-fetal health.
Sera Prognostics, Inc. Appoints Sherree Frazier as Vice President of Sales and Marketing
Jul 2 12
Sera Prognostics, Inc. announced the appointment of Sherree Frazier as Vice President of Sales and Marketing. Ms. Frazier will lead the commercial activities of the organization, including the development and launch of ProNid(TM), Sera's novel diagnostic test to predict preterm birth risk. Before joining Sera, Ms. Frazier served as Senior Director of Molecular Diagnostics and Head of North American Clinical Sales at QIAGEN, Inc. She has extensive experience in the Women's Health field, serving in a number of key leadership capacities including sales, marketing and business development. Prior to QIAGEN, Ms. Frazier served as Women's Health Manager at Adeza Biomedical, where she focused on demand creation for the company's preterm delivery test prior to Adeza's acquisition by Cytyc Corporation in 2007.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 20, 2013